<b>Background/Objectives:</b> Conventional serum biomarkers such as ALT and AST exhibit limited sensitivity and specificity in distinguishing the spectrum of HBV-related liver diseases, especially chronic hepatitis (CHB), cirrhosis (LC), and hepatocellular carcinoma (HCC). This evidence concerns the gene GPT and laryngotracheoesophageal cleft.